New Genomic Test Offers Hope for Breast Cancer Patients in Israel
The test that could save millions of women from chemotherapy and is available in Israel
JpostImage: Jpost
A new genomic test, Prosigna, could help millions of women with breast cancer avoid chemotherapy by accurately assessing the need for treatment. The test analyzes tumor genes to determine recurrence risk, potentially changing treatment approaches and improving patient quality of life.
- 01The Optima study involved over 4,400 breast cancer patients across multiple countries, focusing on hormone-receptor-positive cases.
- 02Results showed that 94% of low-risk patients who avoided chemotherapy remained cancer-free after five years, compared to 95% of those who underwent chemotherapy.
- 03The Prosigna test classifies tumor types and helps personalize treatment decisions, potentially reducing unnecessary chemotherapy.
- 04The test is available in Israel, where it may be covered by health funds for eligible patients diagnosed with early-stage hormonal breast cancer.
- 05The findings will be discussed at the American Society of Clinical Oncology conference, influencing future treatment guidelines.
Advertisement
In-Article Ad
A groundbreaking international study, known as the Optima study, has revealed that the Prosigna genomic test could allow millions of women diagnosed with breast cancer to avoid chemotherapy, which is often accompanied by severe side effects. The study included over 4,400 participants from various countries, primarily focusing on women aged 40 and older with hormone-receptor-positive breast cancer. By analyzing the activity of 50 genes in tumor tissue, the test can determine the risk of cancer recurrence over the next ten years, enabling doctors to tailor treatments more effectively. Results indicated that 94% of women classified as low-risk, who did not undergo chemotherapy, remained cancer-free after five years, nearly matching the 95% survival rate of those who did receive chemotherapy. This significant finding suggests that many women could avoid the physical and emotional toll of chemotherapy without compromising their chances of recovery. The Prosigna test is accessible in Israel, where eligible patients may receive it free of charge through health fund coverage, further promoting personalized medicine in breast cancer treatment.
Advertisement
In-Article Ad
The availability of the Prosigna test in Israel could significantly reduce unnecessary chemotherapy treatments for breast cancer patients, improving their quality of life and reducing healthcare costs.
Advertisement
In-Article Ad
Reader Poll
Do you think genomic testing should be standard practice in breast cancer treatment?
Connecting to poll...
Read the original article
Visit the source for the complete story.